OICR is an innovative translational research institute dedicated to research on the prevention, early detection, diagnosis and treatment of cancer.
Read the Annual Report: PDF [24 MB]
OICR's research focuses on areas with the greatest potential impact on patients.
Programs and Platforms
OICR’s funding from its partners and the Government of Ontario is $160 million, which supports more than 1,400 researchers, clinician-scientists, research staff and trainees.
OICR provides expertise and funding to help researchers further develop and commercialize their cancer research and technologies.
The ICGC is designed to identify cancer-causing mutations involved in more than 25,000 tumours for more than 50 types of cancer.
Learn more about OICR's programs, funding opportunities and careers.
If we can do a better job of determining that there is no residual disease after surgery, then we could potentially spare patients adjuvant radiation therapy.
Learn more about this work
To learn more about OICR's job opportunities, please visit our Careers page.
Learn more about OICR's commercialization program, IPDC Fund and investment opportunities.
Cellax™ is a drug-polymer conjugate nanoparticle that accumulates in tumours, resulting in increased therapeutic benefits and reduced side effects.
Learn more about funding
Learn more about OICR's research, leadership, the latest news items and contact information.
© 2013 Ontario Institute for Cancer Research. All rights reserved.
Funding for the Ontario Institute for Cancer Research is provided by the Government of Ontario